The Diagnostic and Predictive Value of Different Biomarkers in Pancreatic Juice and blood in Patients with Pancreatic Cancer

The incidence of pancreatic cancer (PC) in the Netherlands is low, yet the prognosis is dismal. In 2030, PC is even expected to be the number one cause of cancer related death, worldwide. At present, PC diagnosis is based on imaging, yet the development of biomarkers is needed, not only to enable timely detection, but also to allow personalised care and early prediction of treatment response. Individual biomarkers seem to have a limited predictive value. A broad approach is needed, investigating different molecular markers in different biomaterials (serum and pancreatic juice) to develop a combination of tests that will improve PC survival. We expect to detect cellular and extra-cellular components of the tumour in pancreatic juice and serum (ct-DNA, cytokines, fibrotic mediators), serving as promising targets for biomarker detection.

We hypothesize to find an association between these ct-DNA levels in pancreatic juice and blood and (progression-free) survival.

Pancreatic juice and serum collections will be performed during EUS. Further disease and survival characteristics will be collected up to 2 year after inclusion.

No interventions